{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:13:07Z","timestamp":1788264787223,"version":"build-2803163510"},"reference-count":32,"publisher":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:p>Background: Childhood acute lymphoblastic leukaemia (cALL) tends to metastasize to central nervous system. Treatment with antileukemic agents against CNS leukaemia is an essential component for cure in ALL. Hence, it is essential to identify biomarkers for CNS infiltration. Proteomics, supported by mass spectrometry, is the platform for exploring biomarkers in various biological samples, contributing to translational research. Objectives: This study aimed to identify the plasma proteome profile of children across different risk groups of cALL. Neurexophilin and PC-esterase family, member 3 (NXPE3), was validated. The protein-protein interactions (PPI) of NXPE3 were evaluated with bioinformatics analyses. Methods: Plasma samples from 15 patients with B-ALL standard risk (SR), B-ALL high risk (HR) and T-ALL high risk (HR), were analysed using LC-MS\/MS. NXPE3 protein was validated in all risk groups using ELISA. To compare the NXPE3 values across groups, the Kruskal-Wallis test was applied. A p-value &lt; 0.05 was considered significant. STRING database was used for PPI. Results: LC MS\/MS analysis showed upregulation of NXPE3 in B-ALL SR. Upon ELISA validation, a high plasma concentration of NXPE3 was observed in B-ALL SR, 4.37\u00b11.84 ng\/ml (95% CI 3.31, 5.44), consistent with LC MS\/MS findings. A lower concentration of NXPE3 was observed in B-ALL HR 2.68\u00b11.34 ng\/ml and T-ALL HR 2.38\u00b10.92ng\/ml. The findings were statistically significant. The PPI of NXPE3 highlighted its involvement in multiple processes, including gene expression, cytoskeletal organisation and neuronal function. Conclusion: This is the first report of NXPE3 in cALL. NXPE3 was identified as a potential biomarker for assessing CNS infiltration in cALL. Further studies are recommended to explore its role in leukemogenesis.<\/jats:p>","DOI":"10.36721\/pjps.2026.39.6.176.1","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T09:12:28Z","timestamp":1776935548000},"source":"Crossref","is-referenced-by-count":0,"title":["Proteome-Based Identification And Validation Of NXPE3 In Childhood Acute Lymphoblastic Leukaemia"],"prefix":"10.36721","author":[{"given":"Najia","family":"Tabassum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22735","published-online":{"date-parts":[[2026,4,12]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Aslam S, Shabana  and Ahmed M (2021). Implications of ACMG guidelines to identify high-risk acute lymphoblastic leukemia patients with hereditary cancer susceptibility syndromes (HCSS) in a highly consanguineous population. BMC pediatrics, 21(1): 282.","DOI":"10.1186\/s12887-021-02749-2"},{"key":"ref1","unstructured":"Atlas THP (2025). NXPE3 [Online]. Available: https:\/\/www.proteinatlas.org\/ENSG00000144815-NXPE3\/blood [Accessed 19\/12\/25 2025]."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Bowles KR, Pugh DA, Liu Y, Patel T, Renton AE, Bandres-Ciga S, Gan-Or Z, Heutink P, Siitonen A and Bertelsen S (2022). 17q21. 31 sub-haplotypes underlying H1-associated risk for Parkinson\u2019s disease are associated with LRRC37A\/2 expression in astrocytes. Mol. neurodegener., 17(1): 48.","DOI":"10.1186\/s13024-022-00551-x"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Broto GE, Correa S, Trigo FC, Santos ECD, Tomiotto-Pelissier F, Pavanelli WR, Silveira GF, Abdelhay E and Panis CJ (2020). Comparative analysis of systemic and tumor microenvironment proteomes from children with B-cell acute lymphocytic leukemia at diagnosis and after induction treatment. Front Oncol, 10: 550213.","DOI":"10.3389\/fonc.2020.550213"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Calderon-Rodriguez SI, Sanabria-Salas MC and Umana-Perez AJ (2019). A comparative proteomic study of plasma in Colombian childhood acute lymphoblastic leukemia. Plos one, 14: e0221509.","DOI":"10.1371\/journal.pone.0221509"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Cui M, Cheng C and Zhang L (2022). High-throughput proteomics: A methodological mini-review. Lab Invest, 102(11): 1170-1181.","DOI":"10.1038\/s41374-022-00830-7"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Enlund S, Sinha I, Neofytou C, Amor AR, Papadakis K, Nilsson A, Jiang Q, Hermanson O and Holm F (2024). The CNS microenvironment promotes leukemia cell survival by disrupting tumor suppression and cell cycle regulation in pediatric T-cell acute lymphoblastic leukemia. Exp. Cell Res., 437(2): 114015.","DOI":"10.1016\/j.yexcr.2024.114015"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Gull S, Ahmad A, Iqbal L, Ain RU, Mushtaq W and Faizan M (2025). Treatment-related mortality in pediatric acute-lymphoblastic and myeloid leukemia: Experience from a low-and middle-income setting: Treatment-related mortality in pediatric acute-lymphoblastic and myeloid leukemia. PJHS, 6(7): 114-119.","DOI":"10.54393\/pjhs.v6i7.3125"},{"key":"ref8","unstructured":"Hamad ON, Shamsir MS, Amran S and Abd-Alhasan AQ (2021). Protein network and functional analysis of human leukemia type's interaction. Ann. Rom. Soc. Cell Biol., 25(6): 9756-9770."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Heilmann J, Vieth S, Moricke A, Attarbaschi A, Barbaric D, Bodmer N, Colombini A, Dalla-Pozza L, Elitzur S and Izraeli S (2023). Effect of two additional doses of intrathecal methotrexate during induction therapy on serious infectious toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica, 108(12): 3278.","DOI":"10.3324\/haematol.2022.281788"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Inaba H, Teachey D, Annesley C, Batra S, Beck J, Colace S and Stehman K (2025). Pediatric acute lymphoblastic leukemia, version 2.2025, NCCN clinical practice guidelines in oncology. JNCCN, 23(2): 41-62.","DOI":"10.6004\/jnccn.2025.0006"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Kakaje A, Alhalabi MM, Ghareeb A, Karam B, Mansour B, Zahra B and Hamdan O (2020). Rates and trends of childhood acute lymphoblastic leukaemia: An epidemiology study. Sci. Rep., 10(1): 1-12.","DOI":"10.1038\/s41598-020-63528-0"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Khoja S, Haile MT and Chen LY (2023). Advances in neurexin studies and the emerging role of neurexin-2 in 16: autism spectrum disorder. Front. Mol. Neurosci., 1125087.","DOI":"10.3389\/fnmol.2023.1125087"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Lenk L, Alsadeq A and Schewe DM (2020). Involvement of the central nervous system in acute lymphoblastic leukemia: opinions on molecular mechanisms and clinical implications based on recent data. Cancer Metastasis Rev., 39(1): 173-187.","DOI":"10.1007\/s10555-020-09848-z"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Lu Y, Ma Y, Liu Q and Luo D (2025). Recent progress in mass spectrometry-based liquid biopsy for cancer detection and analysis: A comprehensive review. TrAC Trends Anal. Chem., 190: 118291.","DOI":"10.1016\/j.trac.2025.118291"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Mcgowan-Jordan J, Hastings RJ and Moore S (2020). Iscn 2020: An International System for Human Cytogenomic Nomenclature (2020). Reprint of'Cytogenetic and Genome Research 2020, Vol. 160, No. 7-8'. Karger Medical and Scientific Publishers, Switzerland, pp. 1-376.","DOI":"10.1159\/isbn.978-3-318-06867-2"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Meraj F, Jabbar N, Nadeem K, Taimoor M and Mansoor N (2020). Minimal residual disease in childhood B Lymphoblastic leukemia and its correlation with other risk factors. PJMS, 36(1): 20-26.","DOI":"10.12669\/pjms.36.ICON-Suppl.1721"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Mo F, Ma X, Liu X, Zhou R, Zhao Y and Zhou H (2019). Altered CSF proteomic profiling of paediatric acute lymphocytic leukemia patients with CNS infiltration. Jour. Onco., 2019(1): 3283629.","DOI":"10.1155\/2019\/3283629"},{"key":"ref18","unstructured":"National Library of Medicine. (2025a). MAP9 microtubule associated protein 9 [Homo sapiens (human) [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/gene\/79884 [Accessed 20\/12\/25]."},{"key":"ref19","unstructured":"National Library of Medicine. (2025b). NXPE3 neurexophilin and PC-esterase domain family member 3 [Homo sapiens (human)] [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/gene\/91775 [Accessed 16th June 25]."},{"key":"ref20","unstructured":"National Library of Medicine. (2025c). RPP38 ribonuclease P\/MRP subunit p38 [Homo sapiens (human)] [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/gene\/10557 [Accessed 20\/12\/25 2025]."},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Pastorczak A, Domka K, Fidyt K, Poprzeczko M and Firczuk M (2021). Mechanisms of immune evasion in acute lymphoblastic leukemia. Cancers, 13(7): 1536.","DOI":"10.3390\/cancers13071536"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Piacentini K, Frohlich A, Pfaff A and Koks S (2025). Characterisation of the function of a lncRNA containing SINE-VNTR-Alu 67 to regulate the genes at the MAPT locus. Exp. Bio. Med., 250: 10805.","DOI":"10.3389\/ebm.2025.10805"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Shani S, Gana-Weisz M, Bar-Shira A, Thaler A, Gurevich T, Mirelman A, Giladi N, Alcalay RN, Goldstein O and Orr-Urtreger A (2023). MAPT Locus in Parkinson\u2019s disease patients of Ashkenazi origin: A stratified analysis. Genes, 15(1): 46.","DOI":"10.3390\/genes15010046"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Sjostedt E, Zhong W, Fagerberg L, Karlsson M, Mitsios N, Adori C, Oksvold P, Edfors F, Limiszewska A and Hikmet F (2020). An atlas of the protein-coding genes in the human, pig, and mouse brain. Science, 367(6482): eaay5947.","DOI":"10.1126\/science.aay5947"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Song T, Yao M, Yang Y, Liu Z, Zhang L and Li W (2023). Integrative identification by Hi-C revealed distinct advanced structural variations in lung adenocarcinoma tissue. Phenomics, 3(4): 390-407.","DOI":"10.1007\/s43657-023-00103-3"},{"key":"ref26","unstructured":"Syed A (2025). Proteome-based identification and validation of NXPE3 in childhood acute lymphoblastic leukaemia [Online]. Available: https:\/\/massive.ucsd.edu\/ProteoSAFe\/static\/massive.jsp?redirect=auth [Accessed 16\/02\/26 2025]."},{"key":"ref27","unstructured":"Uniprot. (2025). Q8IVW1 \u00b7 ARL17_HUMAN [Online]. Available: https:\/\/www.uniprot.org\/uniprotkb\/Q8IVW1\/entry [Accessed 20\/12\/25 2025]."},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Wu SY, Short NJ, Nasr L, Dabaja BS and Fang PQ (2022). Central nervous system prophylaxis and treatment in acute leukemias. Curr. Treat. Opt. Onco., 23(12): 1829-1844.","DOI":"10.1007\/s11864-022-01032-5"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Xavier T, Vijayachandran LS, Chandran R, Mony U, Augustine A, Sidharthan N, Ganapathy R, Keechilat P, Sundaram KR and Menon KNJ (2022). Interactome based identification and validation of prefoldin 5-\u03b1 for prognosing CNS leukemia in B-ALL patients.  Sci. Rep., 12: 15491.","DOI":"10.1038\/s41598-022-19489-7"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Zhang M, Ning J, Liu J, Sun Y, Xiao N, Xu H and Chen J (2025). Peripheral blood immune landscape and NXPE3 as a novel biomarker for hypertensive intracerebral hemorrhage risk prediction and targeted therapy. iMeta, 4(3): e70030.","DOI":"10.1002\/imt2.70030"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Zhu S, Xing C, Li R, Cheng Z, Deng M, Luo Y, Li H, Zhang G, Sheng Y and Peng HJ (2022). Proteomic profiling of plasma exosomes from patients with B-cell acute lymphoblastic leukemia. Sci. Rep., 12(1): 11975.","DOI":"10.1038\/s41598-022-16282-4"}],"container-title":["Pakistan Journal of Pharmaceutical Sciences"],"original-title":[],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:16:59Z","timestamp":1788261419000},"score":1,"resource":{"primary":{"URL":"https:\/\/pjps.pk\/single-article?id=7779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,12]]},"references-count":32,"URL":"https:\/\/doi.org\/10.36721\/pjps.2026.39.6.176.1","relation":{},"ISSN":["1011-601X","3105-9686"],"issn-type":[{"value":"1011-601X","type":"print"},{"value":"3105-9686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,12]]}}}